Canada Markets closed

Replimune Group, Inc. (REPL)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
29.61-0.54 (-1.79%)
At close: 4:00PM EDT
29.61 0.00 (0.00%)
After hours: 05:02PM EDT

Replimune Group, Inc.

500 Unicorn Park Drive
3rd Floor
Woburn, MA 01801
United States
781 222 9600

Full Time Employees152

Key Executives

NameTitlePayExercisedYear Born
Mr. Philip Astley-SparkeCEO & Director759.52kN/A1971
Dr. Robert Coffin Ph.D.Founder, Pres, Chief R&D Officer and Director759.52kN/A1965
Ms. Tanya N. Lewis M.S.Chief Devel. Operations Officer16.23kN/A1971
Ms. Jean M. FranchiPrincipal Accounting Officer, CFO, Treasurer, Sec. & Compliance OfficerN/AN/A1966
Dr. Colin A. LoveChief Operating OfficerN/AN/A1958
Dr. Pamela Esposito Ph.D.Chief Bus. OfficerN/AN/A1975
Mr. Sushil Patel Ph.D.Chief Commercial OfficerN/AN/AN/A
Amounts are as of December 31, 2021 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Replimune Group, Inc., a biotechnology company, develops oncolytic immuno-gene therapies to treat cancer. It uses its proprietary Immulytic platform to design and develop product candidates that are intended to activate the immune system against cancer. The company's lead product candidate is RP1, a selectively replicating version of herpes simplex virus 1, which is in Phase I/II clinical trials for a range of solid tumors; and that is in Phase II clinical trials for patients with cutaneous squamous cell carcinoma. It is also developing RP2, which is in Phase I clinical trials for an anti-CTLA-4 antibody-like protein in order to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3 that is in Phase I clinical trials to express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.

Corporate Governance

Replimune Group, Inc.’s ISS Governance QualityScore as of September 26, 2021 is 8. The pillar scores are Audit: 9; Board: 8; Shareholder Rights: 8; Compensation: 8.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.